Literature DB >> 1331308

Detection of HCV RNA in saliva, urine, seminal fluid, and ascites.

T C Liou1, T T Chang, K C Young, X Z Lin, C Y Lin, H L Wu.   

Abstract

Approximately half of the patients with type C hepatitis do not have a history of parenteral exposure. The route of nonparenteral infection remains unknown. To evaluate the possible role of body fluids, the existence of hepatitis C virus (HCV) RNA in saliva, urine, seminal fluid, and ascites was examined by "nested" polymerase chain reaction (PCR). Amplification of the HCV 5' noncoding sequences was carried out. The amplified product was confirmed by Southern blot hybridization and restriction endonuclease digestion. Among 34 patients with chronic liver disease who were positive for anti-HCV and serum HCV RNA, the prevalence of HCV RNA in body fluids was 100% (7/7) in ascites, 48% (15/31) in saliva, 24% (4/17) in seminal fluid, and 7% (2/29) in urine. The body fluids collected from 3 healthy subjects and 5 patients with chronic liver disease who were positive for anti-HCV but negative for serum HCV RNA were all negative for HCV RNA. Hence, the potential infectivity of body fluids in patients testing negative for serum HCV RNA can probably be discounted. Conversely, the presence of HCV RNA in saliva and seminal fluid of patients positive for serum HCV RNA suggests sexual and household contact as likely modes of nonparenteral transmission of type C hepatitis. Furthermore, the high prevalence of HCV RNA in ascites and saliva may have important implications in medical and dental practice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331308     DOI: 10.1002/jmv.1890370309

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  [Postexposure prevention after occupational exposure to HBV, HCV and HIV].

Authors:  U Sarrazin; R Brodt; C Sarrazin; S Zeuzem
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

3.  High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners.

Authors:  P Fabris; D Infantolino; M R Biasin; G Marchelle; E Venza; V Terribile Wiel Marin; P Benedetti; G Tositti; V Manfrin; F de Lalla
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

4.  Quantitative detection of hepatitis C virus (HCV) RNA in saliva and gingival crevicular fluid of HCV-infected patients.

Authors:  Tetsuro Suzuki; Kazuhiko Omata; Tazuko Satoh; Takahiro Miyasaka; Chiaki Arai; Munehiro Maeda; Tomonori Matsuno; Tatsuo Miyamura
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 5.  Sexual transmission of hepatitis C virus infection.

Authors:  G Rooney; R J Gilson
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

6.  Detection and quantitation of hepatitis C virus RNA in feces of chronically infected individuals.

Authors:  M Beld; R Sentjens; S Rebers; J Weel; P Wertheim-van Dillen; C Sol; R Boom
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 7.  Detecting viruses by using salivary diagnostics.

Authors:  Paul L A M Corstjens; William R Abrams; Daniel Malamud
Journal:  J Am Dent Assoc       Date:  2012-10       Impact factor: 3.634

8.  GBV-C RNA presence in several high-risk groups of Spain.

Authors:  E Quirós; G Piédrola; M C Maroto
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

9.  Correlation of hepatitis C antibody levels in gingival crevicular fluid and saliva of hepatitis C seropositive hemodialysis patients.

Authors:  Gökhan Açıkgöz; Murat Inanç Cengiz; Ilker Keskiner; Sereften Açıkgöz; Murat Can; Aydan Açıkgöz
Journal:  Int J Dent       Date:  2009-09-10

Review 10.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.